39 / 61
Volume10, Issue 12 (Suppl)
J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 96
conferenceseries
.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20
th
International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9
th
WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
The possibility of employing micronucleus test for the diagnosis of doubt cases in screening for the
determination of breast cancer
Menicagli Roberto
1
, Menicagli Laura
2
and
Esseridou Anastassia
2
1
Roma Biomed Research Lab, Italy
2
IRCCS Policlinico San Donato, Italy
3
University of Milan, Italy
Introduction & Objectives:
The aim of this study is to check the possibility to use the test with micronuclei (MN) in saliva for
doubt cases (BI-RADS 3) detected in screening for breast cancer.
Material & Methods:
It has been an executed bibliographic search in free text and with the cross referring on PubMed for
articles published from Jan 1, 2000 to Dec 31, 2016, for the keywords: “micronuclei in exfoliated buccal cells in breast cancer”
and also executed preliminary tests on seven patients and, BI-RADS 3 and BI-RADS 2 to evaluate the difference in the score
concerning the presence of micronuclei in the two groups. For the small number of patients, these results are not statistically
reliable but can still sufficiently show a very indicative trend.
Results:
The bibliographic references show as the micronuclei scoring can be used as a biomarker on fine needle aspiration
cytology smears of breast cancer, while the tests in peripheral blood lymphocytes have known reproducibility problem. Also,
the bibliography show in breast cancer, an increase of MN in exfoliated buccal mucosa. Five studies show that the buccal cells
in breast cancer and the amount of MN are significantly higher compared to benign cases as in six studies for the detection
of micronuclei in needle aspiration in ductal carcinoma. Contrasting results are for MN in peripheral blood lymphocytes. On
concerning our preliminary test in buccal cells, three patients of the group BI-RADS 3 show to have micronuclei, while no
positive findings were found in BI-RADS 2.
Conclusions:
May be interesting to apply the MN scoring in cases of doubt, according to functional BI-RADS category 3
(probably benign), and which are sent to a successive control.
Recent Publications
1. Bolognesi C, Bruzzi P, Gismondi V, Volpi S, Viassolo V, Pedemonte S and Varesco L (2014) Clinical application of
micronucleus test: a case-control study on the prediction of breast cancer risk/susceptibility. PLoS One 9(11):e112354.
2. Dey P, Samanta S and Susheilia S (2012) Micronucleus assay in buccal smears of breast carcinoma patients. Diagn.
Cytopathol. 40(8):664-6.
3. Flores Garcia A, et al. (2014) Micronuclei and other nuclear anomalies in exfoliated buccal mucosa cells of Mexican
women with breast cancer. J BUON. 19(4):895-9.
4. Goel S, Bhatia A, Dey P (2013) Spontaneously occurring micronuclei in infiltrating ductal carcinoma of breast: a
potential biomarker for aggressive phenotype detection? Diagn Cytopathol. 41(4):296-302.
5. Hemalatha A, Suresh T N and Harendra Kumar M L (2014) Micronuclei in breast aspirates. Is scoring them helpful?
J Cancer Res Ther. 10(2):309-11.
Biography
Menicagli Roberto has completed his PhD from Milan University and Post-doctoral studies in Biochemistry and Molecular Genetics, at the Faculty of Biology
at Milan University, where he has been a Contract Professor for two years. He is the Director of Roma Biomed Research Lab, Italy a Private Medical Service
Organization. He has published more than 20 papers in reputed journals, some also with impact factor; he is also the principal author of 4 international patents in
the field of environment and of the biomarkers applications. He has been serving as an Editorial Board Member of two magazines concerning the medical sciences.
romabiomedresearch@libero.itMenicagli Roberto et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110